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Problem Identification and Public Health 
Costs
• Human Papillomavirus (HPV) is the most common sexually transmitted infection in United States. Almost all sexually active unvaccinated people will have HPV in their lifetime. 1
• HPV can cause genital warts and certain types of cancers
• 90% of cervical cancers are caused by HPV 2
• Vulvar and vaginal (70%), anal (90%), penile (60%) cancers are due to HPV 2
• Up to 60-70% of oropharyngeal cancers are linked to HPV. Alcohol and tobacco use in combination with HPV infection increases the risk 2
• CDC estimates 34,800 HPV-attributable cancers cases occur per year in the US. 3
• Gardasil-9 Vaccine is FDA approved, given in a 2- to 3-dose series. Demonstrated to be safe and effective at protecting against HPV-related infections and cancers, both cervical 
and non-cervical. 4,5
• Recommended for all children starting ages 11-12 years old. 4
• Vaccine is most effective before exposure to virus, making the vaccination of young children vital for prevention. 6
• Currently available between ages 9-26. Can be given up to age 45 years, although cost effectiveness above age 26 is not yet clear. 7
• Healthy People 2020 goal of 80% of US adolescents 13-15 years old with completed HPV vaccination series. 8
• Vaccination is cost-effective saving up to $35,000 per quality-adjusted life year (QALY) gained. 9
• Barriers to vaccination include parents lack of information about the vaccine, lack of provider recommendation, parents’ concern over giving young children a vaccine related to 
STIs and concern over how vaccination will effect sexual behavior, lack of perceived benefit for males, and difficultly completing the dose series among others. 10
Description of Need in Host Community
A family medicine practice in 
Chittenden County, VT 
• 3rd Quarter 2019: 
• For 13-15 yr old patients, 69.2% had 
received at least one dose of HPV vaccine 
compared to 69.2% for state level. 11
• 50.8% had completed the HPV series 
compared to 52.2% for state level. 11
• Remains below national goal of 80%
• Male vaccination rates are well below 
female rates (over 20% difference)
• Significant percentage of patients who 
started series have not completed it. 11
• Indicates need for interventions to increase 
completion rates
Host Clinic Data from 2015-2017 11
Community Perspective on Barriers to HPV 
Vaccination in Host Clinic
• Family Physician at host clinic: “We 
need a better way to motivate boys 
and parents of young boys to 
vaccinate because the benefit to the 
community is substantial. However, it 
can be harder for them to see the 
personal benefit to vaccination, 
which is contributing to lower 
vaccination rates in males.”
• Physician Assistant at host clinic: 
“Parents often struggle with the 
concept of vaccinating young children 
against infections related to sexual 
activity. Also, completing the series 
can be difficult, and there is need for 
further education and improvements 
in scheduling to increase completion 
rate.”
Intervention and Methodology 
• Obtained data on HPV vaccination rates at the host clinic
• Discussed with providers at the host clinic what challenges to vaccination are 
faced in their community. 
• Researched literature on national HPV vaccination goals and barriers to success. 
Compared this to the barriers faced by the host clinic, and potential opportunities 
for interventions
• A patient educational brochure was developed based on the identified need for 
more information regarding the importance and benefits for vaccinating children. 
Brochure and Responses
“This will be useful in our 
clinic!”
“There is always a need for more 
patient education materials. This 
topic is definitely an area of 
need.”
Evaluation of Effectiveness and Limitations 
• The measurement of vaccination rates in future quarters can be compared to current rates to see if there was an 
improvement.
• Evaluating the amount of brochures taken from the clinic can gage interest in the information, and help determine 
the best locations to present them (patient rooms, waiting room/front desk, bathrooms, handed out by staff).
• Limitations of this project 
• Due to the short time scope of this project, there was an inability to adequately measure the effectiveness in 
improving vaccination rates. This can be evaluated in the future
• Does not study whether there are better methods for delivering this information to patients, along with how 
to best get this information to the patients on the fence about vaccination, whose decisions are most likely to 
be impacted by further education.
• Only addresses patient education of the identified obstacles. Does not address other barriers such as 
scheduling for completion of series, provider interactions, individual cost barriers, and many others
Recommendations for Future 
Interventions/Projects 
• Creating an automatic scheduling system for follow-up doses upon initiation of 
the first dose in the series
• Creation of other methods for delivering the information such as posters. 
Information from the brochure could also be adapted to the clinic’s website for 
patients to access online. 
• Expanding this educational initiative to other places such as schools, or 
pharmacies. 
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